Objective: The objective of the study was to identify possible toxic signal induced by cyclophosphamide treatment by searching database from Canadian Adverse Reaction Monitoring Program (CADRMP). Methods: A total of 10429 reports of patients between January 1970 to March 2010 were downloaded from CADRMP website. These reports contained information of adverse events associated with all other drugs inclusive of cyclophosphamide . Adverse drug reaction (ADR) signal detection were determined by proportional reporting ratio (PRR), reporting odds ratio (ROR), PRR calculated by chisquare statistics, 95% confidence interval of PRR, observed to expected (O/E) ratio and De Mouchel method calculated PRR. Information component (IC) was given by Bayesian confidence propagation neural network. (As per regulatory criteria, PRR ≥ 2, ROR ≥ 1, chi-square statistics calculated PRR ≥ 4 and lower bound of 95% CI of PRR ≥ 1 to consider particular adverse drug reaction as a signal. Further by BCPNN method, if IC−2SD≤0 then that drug-ADR pair considered as no signal; if 0<IC−2SD ≤ 1.5, then that drug-ADR pair considered as weak signal; if 1.5<IC−2SD ≤ 3.0, then that drug-ADR pair considered as middle signal; if IC−2SD > 3.0, then that drug-ADR pair considered as strong signal). Results: A total of 108 reports of cyclophosphamide-induced neutropenia were reported in CADRMP database. The PRR was found to be 4.7396 and by the Du Mouchel method it was 3.9310. Further, the PRR calculated by chi-square statistics was 236.02518. The lower and upper limits of 95% CI of PRR was found to be 1.3484 and 1.7634, respectively. The O/E ratio was found to be 3.9322 and ROR was found to be 4.9704. The value of PRR ≥ 2, ROR ≥ 1, chi-square statistics calculated PRR ≥ 4 and lower limit of 95% CI of PRR ≥ 1 indicates signal for neutropenia caused by cyclophosphamide. The value of IC-2SD was 1.6852 indicates middle signal for cyclophosphamide-induced neutropenia. The signal of neutropenia coupled with cyclophosphamide was found potent enough to cause neutropenia in Canadian population.
INTRODUCTION
Signal detection in pharmacovigilance comprises the processes of selection of a drug-adverse event association of possible interest; the preliminary assessment of the available evidence; and a follow-up of how the signal develops. In the currently used automated systems, the computer selects drug-adverse event pairs that stand out against the background of the database, according prefixed statistical criteria, for example, using proportional reporting ratio (PRR) or, as is the case at the UMC, the information component (IC) calculated by a Bayesian Confidence Propagation Neural Network (BCPNN). Once the computer has at a given moment identified the associations that meet the quantitative criterion, individual assessors have to select those associations that deserve further preliminary attention. From now on the human mind has to decide whether the association is likely or not to represent a true signal and needs further examination. 1 Cyclophosphamide is an inactive pro-drug that requires enzymatic and chemical activation; the resultant nitrogen mustard produces the interstrand and intrastrand DNA cross links that account for its cytotoxic properties. The major mechanism of cyclophosphamide detoxification involves aldehyde dehydrogenase; cells with high proliferative potential express high levels of aldehyde dehydrogenase and as a consequence are relatively resistant to cyclophosphamide. Cyclophosphamide, in combination with other antineoplastic agents, is used for the treatment of various cancers, including breast, lymphoid and pediatric malignancies. Cyclophosphamide is also widely used in bone marrow transplantation 'conditioning' and 'mobilization' regimens, and for the treatment of different autoimmune conditions. The toxic effects of cyclophosphamide include bone marrow suppression, cardiac and gonadal toxicity, hemorrhagic cystitis and carcinogenesis, with cumulative dose being the principal risk factor. 2 Bone marrow suppression is the most common toxic effect of cyclophosphamide. Neutropenia is dose dependent. Patients treated with low dose cyclophosphamide should be monitored closely, although they rarely develop significant neutropenia. Leukopenia, thrombocytopenia and anemia are common after high dose cyclophosphamide administration. 2 Rapid hematologic recovery invariably occurs within 2-3 weeks in patients with normal bone marrow reserve; regardless of the dose. 2 The objective of the study was to identify possible toxic signal detection (SD) of cyclophosphamide by searching database from Canadian Adverse Reaction Monitoring Program (CADRMP).
MATERIALS AND METHODS

Data collection from public database
The CADRMP is the Health Canada post-marketing surveillance program which collects and assesses suspected adverse reaction reports for Canadian marketed health products such as cyclophosphamide. Data was extracted from Canadian Adverse Drug Reaction Monitoring Program. For extraction following sections were serially accessed from health Canada website (http://www.hc-sc. gc.ca/index-eng.php). 3 In the section of Canada vigilance program, the CADRMP online database was extracted.
Procedure followed for signal detection
Individual Case Safety Reports (ICSRs) in this database were collected from the official website of Health Canada. The text freely available was converted into a structured format. In the structured format, statistical methods were applied to calculate an actual measure of signals. Therapeutic class-specific SD calculations were then carried out as shown in Figure 1 . For analysis of detection of signals by different methods are reported. These methods of calculations were selected following a systematic literature review. [4] [5] [6] In the present study, attempt was made to maintain the originality of data collected from CADRMP database while computing actual SD. 
ROR calculation
The procedure followed to calculate ROR was similar to that of the PRR method. 4 The same contingency 
Calculation of signal detection
Disproportionality
These are the frequency or relative frequency of a particular drug-event pair. The signal would be considered significant if the statistics from different calculations such as Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), PRR calculated by chi-square statistics, the 95% confidence interval for PRR (lower limit and upper limit), the observed-to-expected (O/E ratio) and DuMouchel method calculated PRR exceeded a certain value ((As per regulatory criteria, PRR ≥ 2, ROR ≥ 1, chi-square statistics calculated PRR ≥ 4 and lower bound limit of 95% CI of PRR ≥ 1 to consider particular adverse drug reaction as a signal. Further by BCPNN method, if IC−2SD ≤ 0 then that drug-ADR pair considered as no signal; if 0 < IC−2SD ≤ 1.5, then that drug-ADR pair considered as weak signal; if 1.5 < IC−2SD ≤ 3.0, then that drug-ADR pair considered as middle signal; if IC − 2SD > 3.0, then that drug-ADR pair considered as strong signal), then the signal would be considered significant.
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PRR calculation
As shown in Table 1 and 2, a 2*2 contingency table was prepared to capture the incidences of neutropenia (targeted event Y) and all other events for the targeted drug X, i.e., cyclphosphamide, and all other drugs in the database to calculate PRR. 4 After that, the PRR was calculated as follows:
a=Targeted event (Y) associated with targeted drug b=Other adverse drug reactions (ADRs) associated with targeted drug The 95% CI for ln (PRR) was then estimated as ln (PRR) ± 1.96SE, and its exponential was taken. 7 Lower and upper limits of 95% CI for PRR = {PRR/exp (1.96SE), PRR / exp (1.96SE)}
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The observed-to-expected (O/E) ratio calculation 8 The O/E was calculated as follows: 
Statistical calculation
The statistical significance of PRR, ROR, Chi-square calculated PRR, O/E ratio, Du-Mouchel calculated PRR and information component statistics by BCPNN method was based on regulatory guidelines. 6 
RESULTS
Proportional reporting ratio (PRR) and Reporting odds ratio (ROR)
The total of 10429 patient's reports were extracted from CADRMP. 1842 (100%) reports of adverse event associated with cyclophosphamide inclusive neutropenia were noted. The relevant details for calculation of PRR and ROR are mentioned in Table 1 and 2. The signal detected with the help of "proportional reporting ratio" for neutropenia associated with cyclophosphamide was found to be 4.7396 and "reporting odds ratio" for neutropenia associated with cyclophosphamide was found to be 4.9704. However, the PRR with the help of the Du Mouchel Method was found to be 3.9310. As per above results, the value of PRR was ≥ 2 and value of ROR was ≥ 1 indicate toxic signal for neutropenia associated with cyclophosphamide.
Chi-square statistics calculated PRR
The relevant details for calculation of Chi-square statistics calculated PRR is mentioned in Table 3 . The chi-square statistics calculated PRR was 236.02518. The value of chi-square statistics calculated PRR was ≥ 4 for cyclophosphamide which also indicates toxic signal for neutropenia associated with cyclophosphamide.
95% Confidence interval for PRR
The lower limit of 95% Confidence Interval of PRR was found to be 1.3484 and Upper limit was found to be 1.7634. The lower limit of 95% CI of PRR was ≥ 1 for cyclophosphamide-induced neutropenia.
Observed to expected ratio
The Observed-to-expected ratio of PRR was found to be 3.9322. Observed to expected ratio has been computed as per mentioned below steps:
Data by gender and age
The data obtained from CADRMP were stratified by years ( Figure 2 ), age ( Figure 3 ) and gender ( 
Signal Detection by Bayesian Confidence Propagation Neural Network
The details of signal detection by BCPNN method and relevant parameters for cyclophosphamide were mentioned in Table 5 and 6. The value of IC is 1.9811, the value of IC-2SD is observed 1.3484 means middle signal for neutropenia at the Canadian data base.
The conclusive summary of signal detection for cyclophosphamide was mentioned in Table 7 .
Adverse event evaluation
All patients reported at least one adverse event (AE). Listing of AEs was done according to the system or organ class ( 
Statistical analysis
As per statistical analysis by SAS version 9.2 software, the Chi square value was observed 253.50 that was higher than 4 (Chi square should be ≥ 4 as per regulatory guideline for Signal
5
) which was further supported by P value<0.001 who showed significant signal of neutropenia associated with cyclophosphamide.
DISCUSSION
The thalidomide disaster in the early 1960s prompted drug authorities to develop systems for detection of unknown side effects and risks of drugs. Spontaneous reporting systems have since been established in more than 100 countries. Signal detection in spontaneous reporting databases has proven to be a simple and cost effective tool for identifying suspected new adverse drug reactions. Some of the better known examples of safety signals detected include apart from phocomelia from thalidomide during pregnancy, vaginal clear cell cancer in girls of mothers using diethylstilbestrol during pregnancy, suicidal ideation and suicide induced by the anti-obesity drug rimonabant and the latest example; narcolepsy in relation to the pandemic vaccine Pandemrix.
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The spontaneous reporting systems differ by country regarding accepted reporters (e.g., physicians, pharmacists, consumers) and the managing of the systems (national authorities, university based or independent institutions). A few standardized terminologies for coding adverse events and drugs are applied, which lend the opportunity to assemble and analyzed information from different sources to detect and act on new safety signals. The original signal detection method of case-by-case assessment of spontaneous reports of adverse drug reactions (ADR) is effective, but resource consuming, especially in large ADR databases with high volumes of incoming reports. 9 This has led to the development and acceptance of semiautomated signal detection methods, including primary step(s) of detection by statistical Disproportionality analysis, followed by manual clinical validation. Several statistical methods are currently in use.
7-10 but no gold standard has been established. [10] [11] The methods have the ability to detect new safety signals for drugs years earlier than traditional manual methods. [12] [13] Strengths, limitations and differences between different pharmacovigilance signal detection methods including their initial disproportionality part have been analyzed and described previously (CIOMS 2010). Within the European Union (EU) signal detection is continuously performed in the common ADR database EudraVigilance (EV, EV2013) using the Proportional Reporting Ratio (PRR) method. 
CONCLUSION
The therapeutic class specific signal of neutropenia coupled with cyclophosphamide was found potent enough to cause neutropenia.
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